Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | BID | P55957 | 3/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.42 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.42 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17027766 | 0.98 | LIPG (0.58) | LIPGNR1H2NR1H3ALOX5PTGS2 | |
| SCHEMBL17027755 | 0.98 | LIPG (0.58) | LIPGNR1H2NR1H3ALOX5PTGS2 | |
| SCHEMBL9579594 | 0.98 | LIPG (0.58) | LIPGNR1H2NR1H3ALOX5PTGS2 | |
| SCHEMBL17027770 | 0.98 | LIPG (0.58) | LIPGNR1H2NR1H3ALOX5PTGS2 | |
| SCHEMBL17027739 | 0.98 | LIPG (0.58) | LIPGNR1H2NR1H3ALOX5PTGS2 | |
| SCHEMBL11354772 | 0.98 | LIPG (0.58) | LIPGNR1H2NR1H3ALOX5PTGS2 | |
| SCHEMBL1920592 | 0.93 | LIPG (0.47) | LIPGNR1H2NR1H3ALOX5PTGS2 | |
| SCHEMBL30037094 | 0.89 | LIPG (0.65) | LIPGNR1H2NR1H3ALOX5PTGS2 | |
| SCHEMBL82794 | 0.89 | LIPG (0.65) | LIPGNR1H2NR1H3ALOX5PTGS2 | |
| SCHEMBL10831024 | 0.87 | LIPG (0.55) | LIPGNR1H2NR1H3ALOX5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447459-A | Method for synthesizing rotigorskite key intermediate by using chiral phase transfer catalyst as catalyst | 瑞博(杭州)医药科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-112960656-A | Preparation method of vanadium nitride nanoparticle composite material for lithium-sulfur battery | 福建师范大学 | 2021-06-15 | — | — | CN | claimed |
| CN-117943115-A | Chiral quaternary ammonium salt phase transfer catalyst, and preparation method and application thereof | 西湖大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-117550998-A | Method for synthesizing S-2, 6-dimethyl tyrosine derivative by using novel chiral phase transfer catalyst | 瑞博(杭州)医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117447459-A | Method for synthesizing rotigorskite key intermediate by using chiral phase transfer catalyst as catalyst | 瑞博(杭州)医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116854667-A | Proteolytic targeted chimera for targeted degradation of PD-L1 and application thereof | 浙江工业大学 | 2023-10-10 | — | — | CN | disclosed |
| CN-110869369-B | Five-membered and six-membered nitrogen heteroaromatic ring compound, preparation method thereof, medicinal composition and application thereof | 厦门大学 | 2022-06-28 | — | — | CN | disclosed |
| CN-112960656-A | Preparation method of vanadium nitride nanoparticle composite material for lithium-sulfur battery | 福建师范大学 | 2021-06-15 | — | — | CN | disclosed |
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | Amcure Biosciences Pte. Ltd. (SG) | 2020-06-04 | — | — | US | disclosed |
| EP-3626718-A1 | FIVE- AND SIX-MEMBERED AZA-AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATION | Xiamen University (CN) | 2020-03-25 | — | — | EP | disclosed |
| CN-110869369-A | Five-membered and six-membered nitrogen heteroaromatic ring compound, preparation method thereof, medicinal composition and application thereof | 厦门大学 | 2020-03-06 | — | — | CN | disclosed |
| US-20150065703-A1 | 7-MEMBERED FUSED HETEROCYCLES AND METHODS OF THEIR SYNTHESIS | NORTHWESTERN UNIVERSITY (US) | 2015-03-05 | — | — | US | disclosed |
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
| EP-0399633-B1 | Leukotriene B4 derivatives, process for their preparation and their use as medicines | SCHERING AG (DE) | 1994-11-30 | — | — | EP | disclosed |
| US-5187286-A | LEUKOTRIENE-B4 DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-02-16 | — | — | US | disclosed |
| WO-1990014329-A1 | LEUKOTRIENE B4 DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1990-11-29 | — | — | WO | disclosed |
| EP-0399633-A1 | Leukotriene B4 derivatives, process for their preparation and their use as medicines | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | MC1R, MCHR2, MCHR1 | LIPG 1106/4885NR1H2 728/4885NR1H3 1091/4885 |
| US-20150065703-A1 | 7-MEMBERED FUSED HETEROCYCLES AND METHODS OF THEIR SYNTHESIS | HTR7, CDK7, CBX7 | LIPG 4012/4885NR1H2 2306/4885NR1H3 2349/4885 |
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | KRAS, NRAS, RASSF5 | LIPG 3567/4885NR1H2 3553/4885NR1H3 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.